Advertisement

Untersuchungen zur cGMP-stimulierenden Wirkung von Pentaerithrityltetranitrat und seinen Metaboliten in kultivierten LLC-PK1-Zellen

  • B. Hinz
  • H. Schröder

Zusammenfassung

Die seit mehr als hundert Jahren zur Therapie der koronaren Herzkrankheit und ihres wichtigsten Symptoms, der Angina pectoris, eingesetzten organischen Nitrate sind Prodrugs, die Stickstoffmonoxid (NO) präformiert als aktiven Metaboliten enthalten und im Organismus freisetzen (Übersichten: Schröder 1996; Hinz und Schröder 1997a). Studien der siebziger Jahre zeigten, daß das freie NO-Radikal über Aktivierung der löslichen Guanolylcyclase die Synthese des intrazellulären „second messengers“ cyclisches Guanosinmonophosphat (cGMP) hervorruft (Arnold et al. 1977, Gruetter et al. 1979). In diesem Zusammenhang konnte demonstriert werden, daß durch Glyceroltrinitrat und andere NO-Donoren hervorgerufene Effekte wie Relaxation der glatten Gefaßmuskulatur und Hemmung der Thrombozytenaggregation ursächlich mit einer Steigerung der intrazellulären cGMP-Synthese zusammenhangen (Arnold et al. 1977, Böhme et al. 1978, Kukovetz et al. 1979, Schultz et al. 1977).

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Arnold WP, Mittal CK, Katsuki S, Murad F (1977) Nitric oxide activates guanylate cyclase and increases guanosine 3’:5’-cyclic monophosphate levels in various tissue preparations. Proc Natl Acad Sci USA 74: 3203–3207PubMedCrossRefGoogle Scholar
  2. Bennett BM, Leitman DC, Schröder H, Kawamoto JH, Nakatsu K, Murad F (1989) Relationship between biotransformation of glyceryl trinitrate and cyclic GMP accumulation in various cultured cell lines. J Pharmacol Exp Ther 250: 316–323PubMedGoogle Scholar
  3. Böhme E, Graf H, Schultz G (1978) Effects of sodium nitroprusside and other smooth muscle relaxants on cyclic GMP formation in smooth muscle and platelets. Adv Cyclic Nucleotide Res 9: 131–143PubMedGoogle Scholar
  4. Commarato MA, Winbury MM, Kaplan HR (1973) Glyceryl trinitrate and pentrinitrol (pentaerythritol trinitrate): Comparative cardiovascular effects in dog, cat and rat by different routes of administration. J Pharmacol Exp Ther 187: 300–307Google Scholar
  5. Crew MC, Gala RL, Haynes LJ, Di Carlo FJ (1971) Biliary excretion and biotransformation of pentaerythritol trinitrate in rats. Biochem Pharmacol 20: 3077–3089PubMedCrossRefGoogle Scholar
  6. Crew MC, Melgar MD, Di Carlo M, Di Carlo FJ (1975) Pentaerythritol tetranitrate and metabolites in rat plasma. J Pharmacol Exp Ther 192: 218–223PubMedGoogle Scholar
  7. Davidson IWF, Miller HS, Di Carlo FJ (1971) Pharmacodynamics and biotransformation of pentaerythritol tetranitrate in man. J Pharm Sci 60: 274–277PubMedCrossRefGoogle Scholar
  8. Di Carlo FJ, Crew MC, Brusco LS, Davidson IW (1977) Metabolism of pentaerythritol trinitrate. Clin Pharmacol Ther 22: 309–315PubMedGoogle Scholar
  9. Di Carlo FJ, Crew MC, Coutinho CB, Haynes LJ, Sklow NJ (1967) The absorption and biotransformation of pentaerythritol tetranitrate-1,2-14C by rats. Biochem Pharmacol 16: 309–316CrossRefGoogle Scholar
  10. Di Carlo FJ, Crew MC, Sklow NJ, Coutinho CB, Nonkin P, Simon F, Bernstein A (1966) Metabolism of pentaerythritol tetranitrate by patients with coronary artery disease. J Pharmacol Exp Ther 153: 254–258Google Scholar
  11. Di Carlo FJ, Hartigan JM Jr, Coutinho CB, Phillips GE (1965) Absorption, distribution and excretion of pentaerythritol and pentaerythritol tetranitrate by mice. Proc Soc Exp Biol Med 118: 311–315Google Scholar
  12. Gruetter CA, Barry BK, McNamara DB, Gruetter DY, Kadowitz PJ, Ignarro LJ (1979) Relaxation of bovine coronary arterial guanylate cyclase by nitric oxide, nitroprusside and a carcinogenic nitrosamine. J Cyclic Nucleotide Res 5: 211–224PubMedGoogle Scholar
  13. Hinz B, Schröder H (1997a) Glyceroltrinitrat. Dtsch Med Wschr 122: 1047–1048PubMedGoogle Scholar
  14. Hinz B, Schröder H (1997a) Glyceroltrinitrat. Dtsch Med Wschr 122: 1047–1048Google Scholar
  15. Hinz B, Schröder H (1998) Vitamin C attenuates nitrate tolerance independently of its antioxidant effect. FEBS Lett 428: 97–99PubMedCrossRefGoogle Scholar
  16. Kukovetz WR, Holzmann S, Wurm A, Pöch G (1979) Evidence for cyclic GMP-mediated relaxant effects of nitro-compounds in coronary smooth muscle. Naunyn-Schmiedeberg’s Arch Pharmacol 310: 129–138PubMedCrossRefGoogle Scholar
  17. Melgar MD, Leinweber F-J, Crew MC, Di Carlo FJ (1974) Denitration of unconjugated and conjugated pentaerythritol nitrates by rat liver cytosol. Drug Metab Disp 2: 46–52Google Scholar
  18. Noack E, Kojda G (1994) Pentaerithrityltetranitrat. Gesichertes und Neues zur Pharmakologie eines Langzeitnitrats. Steinkopff Verlag DarmstadtCrossRefGoogle Scholar
  19. Parker JC, Chang Y-C, Davidson IWF (1973) Coronary vasodilator activity of pentaerythritol trinitrate and its metabolites assayed in the dog. Fed Proc 32: 794Google Scholar
  20. Schroder H (1996) Bioactivation of organic nitrates and other nitrovasodilators. Adv Drug Res 28: 253–267CrossRefGoogle Scholar
  21. Schröder H, Leitman DC, Hay ward LD, Bennett BM, Murad F (1987) Cultured rat lung fibroblasts as a model for organic nitrate-induced cyclic GMP accumulation and activation of guanylate cyclase. J Appl Cardiol 2: 301–311Google Scholar
  22. Schröder H, Leitman DC, Bennett BM, Waldman SA, Murad F (1988) Glyceryl trinitrate-induced desensitization of guanylate cyclase in cultured rat lung fibroblasts. J Pharmacol Exp Ther 24: 413–418Google Scholar
  23. Schröder H, Schrör K (1990) Inhibitors of cytochrome P-450 reduce cyclic GMP stimulation by glyceryl trinitrate in LLC-PK1 kidney epithelial cells. Naunyn-Schmiedeberg’s Arch Pharmacol 342: 616–618PubMedGoogle Scholar
  24. Schultz K-D, Schultz K, Schultz G (1977) Sodium nitroprusside and other smooth muscle relaxants increase cyclic GMP levels in rat ductus deferens. Nature 265: 750–751PubMedCrossRefGoogle Scholar
  25. Steiner AL, Parker CW, Kipnis DM (1972) Radioimmunoassay for cyclic nucleotides. J Biol Chem 247: 1106–1113PubMedGoogle Scholar
  26. Weber W, Michaelis K, Luckow V, Kuntze U, Stalleicken D (1995) Pharmacokinetics and bioavailability of pentaerithrityl tetranitrate and two of its metabolites. Arzneim Forsch/Drug Res 45: 781–784Google Scholar

Copyright information

© Dr. Dietrich Steinkopff Verlag, Darmstadt 1998

Authors and Affiliations

  • B. Hinz
  • H. Schröder

There are no affiliations available

Personalised recommendations